Letrozole,
does it really help with Increased ovulation and live birth in women with anovulatory PCOS infertility?
research showsLetrozole is rated A because it increases ovulation and live birth in anovulatory PCOS infertility. In a 750-participant NIH-supported multicenter double-blind trial, cumulative live birth was 27.5% with letrozole versus 19.1% with clomiphene, for a rate ratio of 1.44, and cumulative ovulation was 61.7% versus 48.3%. The 2022 Cochrane review confirmed higher live birth versus SERMs, OR 1.72 across 11 trials and 2,060 participants with high certainty, and clinical pregnancy, OR 1.69. Agreement between a direct live-birth endpoint and an independent publicly funded large trial supports A; off-label regulatory status is separate from efficacy.
ads claimCalling letrozole a pregnancy-success drug turns a higher average probability into an individual guarantee. It does not correct tubal blockage, severe male-factor infertility, or age-related ovarian decline.
Useful facts when choosing a product
- For PCOS ovulation induction, letrozole is commonly started at 2.5 mg for five days early in the menstrual cycle, with dose and monitoring individualized by a fertility clinician.
- Its principal labeled indication is hormone-receptor-positive breast cancer, and ovulation induction may be off-label in Korea and other jurisdictions.
- Pregnancy should be excluded before treatment, and letrozole should not be continued during pregnancy; timing and exposure management should follow the prescriber.
- Hot flushes, fatigue, dizziness, and headache can occur, and multiple pregnancy is not eliminated, so follicular response and pregnancy require follow-up.
What the research actually shows
Legro 2014 double-blind randomized 750 women aged 18 to 40 to letrozole or clomiphene. Live birth was 103 of 374 versus 72 of 376, and cumulative ovulation was 834 of 1,352 cycles versus 688 of 1,425 cycles. Twin pregnancy was 3.4% versus 7.4%, although that comparison was not confirmatory. The 2022 Cochrane review assessed 41 trials and 6,522 women and rated the direct SERM-comparison live-birth and pregnancy evidence as high certainty. A separate 2023 meta-analysis also reported a live-birth risk ratio of 1.49.
Why this is classified as A (86)
An independent publicly funded 750-participant multicenter trial showed superiority on the direct clinical endpoint of live birth, and high-certainty Cochrane evidence across 11 trials and 2,060 participants consistently supported it, giving A with 86 points. Off-label status and adverse effects are separate safety issues.
Counterpoint. Optimizing weight and metabolic health, checking tubes, uterus, and semen, confirming ovulation, and planning escalation remain as important as selecting the drug.
Rejudgment record. New verdict — Assigned A for superiority on direct live birth in a publicly funded large multicenter double-blind trial and consistent high-certainty Cochrane evidence after problematic trials were filtered
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Increased ovulation in anovulatory PCOS | A | A large trial and multiple-trial syntheses consistently found an increase. |
| Increased live birth in anovulatory PCOS | A | An independent large trial on direct live birth agrees with high-certainty meta-analysis. |
| Superiority to clomiphene | A | Live birth of 27.5% versus 19.1% and pooled OR 1.72 support superiority. |
| Complete prevention of multiple pregnancy | D | Twin pregnancy was numerically lower but not zero and was not a confirmatory superiority endpoint. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Legro RS et al. 2014 PPCOS II | Multicenter randomized double-blind active-controlled trial | 750 | Public funding including the United States NICHD | Cumulative live birth and ovulation over up to five cycles | Live birth was 27.5% versus 19.1%, rate ratio 1.44; ovulation was 61.7% versus 48.3%. | Key independent large hard-endpoint trial |
| Franik S et al. 2022 Cochrane review | Systematic review and meta-analysis of randomized trials | 2,060 | Academic Cochrane synthesis | Live birth, clinical pregnancy, miscarriage, multiple pregnancy, and OHSS | Live birth OR was 1.72 and clinical pregnancy OR was 1.69, both with high certainty. | Key high-certainty synthesis |
| Liu Z et al. 2023 | Systematic review and meta-analysis of randomized trials | 3,952 | Academic research | Ovulation, clinical pregnancy, and live birth | Letrozole favored live birth RR 1.49, clinical pregnancy RR 1.48, and ovulation RR 1.14. | Independent synthesis replication |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Letrozole x increased ovulation and live birth in anovulatory PCOS infertility — Evidence Grade A·86. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/letrozole-pcos-anovulatory-infertility-ovulation-live-birth/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.